date,title,source
Nov-13-18,"Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer",GlobeNewswire
Dec-03-18,What Kind Of Shareholders Own Veru Inc (NASDAQ:VERU)?,Simply Wall St.
Dec-03-18,Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil  Finasteride Tablet for Benign Prostatic Hyperplasia,GlobeNewswire
Dec-13-18,Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter,GlobeNewswire
Jan-14-19,Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia,GlobeNewswire
Jan-15-19,Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019,GlobeNewswire
Jan-18-19,"Before You Buy Veru Inc. (NASDAQ:VERU), Consider Its Volatility",Simply Wall St.
Jan-22-19,"Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer",GlobeNewswire
